



tes in mice. Clin Cancer Res. 1999; 5(10): 2918–2924.

**16.** Jaiswal P, Attar BM, Yap JE, et al. Acute liver failure with amiodarone infusion: A case report and systematic review. J Clin Pharm Ther. 2018; 43(1): 129–133.

**17.** Breuer HW, Bossek W, Haferland C, et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther. 1998; 36(6): 350–352.

**18.** Lu J, Jones AD, Harkema JR, et al. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012; 125(1): 126–133.

**19.** Morelli S, Guido V, De Marzio P, et al. Early hepatitis during intravenous amiodarone administration. Cardiology. 1991; 78(3): 291–294.

**20.** Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003; 82(6): 392–406.

**21.** Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity likely due to ischemic hepatitis. Isr Med Assoc J. 2011; 13(12): 748–752.

**22.** Guglin M. Intravenous amiodarone: offender or bystander? Crit Care Med. 2005; 33(1): 245–246.